Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Rhea-AI Summary
Citius Oncology (Nasdaq: CTOR) reported fiscal 2025 results and a business update following the U.S. commercial launch of LYMPHIR in December 2025 for relapsed/refractory Stage I–III CTCL after ≥1 prior systemic therapy. The company closed $36M in strategic financings (three offerings in July, Sept, Dec 2025) and received a $1M note from parent Citius Pharma to support commercialization. Cash was $3.9M as of Sept 30, 2025. FY25 R&D was $6.4M, G&A $8.8M, stock-based comp $8.3M, and net loss was $24.8M (‑$0.34/share). Company announced U.S. wholesaler agreements, 19-market named patient programs, an AI commercial collaboration, and preliminary combo trial results.
Positive
- U.S. commercial launch of LYMPHIR in December 2025
- Closed $36 million in strategic financings to support commercialization
- Distribution agreements with three leading U.S. wholesalers
- Access arranged in 19 international markets via Named Patient Programs
- Collaboration with Verix to deploy AI-driven commercial targeting
Negative
- Cash and cash equivalents were $3.9 million as of Sept 30, 2025
- Net loss widened to $24.8 million in FY25 (‑$0.34/share)
- R&D, G&A, and stock-based comp increased versus prior year
News Market Reaction – CTOR
On the day this news was published, CTOR gained 1.60%, reflecting a mild positive market reaction. Argus tracked a trough of -7.7% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $108M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CTOR fell 10.07% while key peers showed smaller mixed moves (e.g., BIOA -2.8%, IRWD -1.23%, ANIK -0.32%, DERM +0.13%), pointing to a stock-specific reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Conference participation | Positive | +8.0% | ASH meeting presence highlighting FDA‑approved LYMPHIR and upcoming Q4 2025 launch. |
| Dec 01 | Product launch | Positive | +19.7% | U.S. commercial launch of LYMPHIR for relapsed or refractory CTCL. |
| Dec 04 | Distribution deal | Positive | -8.2% | Exclusive Er‑Kim agreement expanding LYMPHIR access to 19 international markets. |
| Dec 09 | Financing announced | Negative | +6.4% | Announcement of $18M concurrent registered direct offering and private placement. |
| Dec 10 | Financing closed | Negative | -2.6% | Closing of $18M equity financing and warrant amendments to fund LYMPHIR launch. |
Recent CTOR news has produced mixed reactions, with both strong gains and sharp selloffs on generally positive commercial updates, and typical pressure around financing events.
Over the last month, CTOR has focused on commercializing LYMPHIR™ and expanding access. The company exhibited at ASH in late November 2025, then announced the U.S. commercial launch of LYMPHIR on Dec 1, which coincided with a strong positive price move. Subsequent international distribution expansion to 19 markets and an $18 million financing drew more muted or negative reactions. Today’s full-year FY25 results and business update build on this commercialization and financing narrative.
Market Pulse Summary
This announcement details CTOR’s shift to a revenue-generating model following the U.S. launch of LYMPHIR™, alongside FY25 financials that show a $24.8 million net loss and higher operating expenses. The company bolstered liquidity with $36 million in financings and ended the year with $3.9 million in cash, while expanding distribution and reporting early combination‑therapy data. Investors may focus on adoption trends, expense discipline, and future capital needs when assessing this trajectory.
Key Terms
il-2 receptor-directed immunotherapy medical
cutaneous t‑cell lymphoma medical
named patient programs regulatory
private placement financial
registered direct offering financial
public offering financial
note payable financial
phase i clinical trial medical
AI-generated analysis. Not financial advice.
Cancer Immunotherapy, LYMPHIR™, launched in the
Completed
"2025 was a landmark year for Citius Oncology. With the
Fiscal Year 2025 Business Highlights and Subsequent Developments
- Launched LYMPHIR™ (denileukin diftitox-cxdl), a novel IL‑2 receptor-directed immunotherapy, in the
U.S. in December 2025 for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous T‑cell lymphoma (CTCL) after at least one prior systemic therapy; - Executed service agreements with the three leading
U.S. pharmaceutical wholesalers to distribute LYMPHIR to healthcare organizations, including major medical centers and specialized hospitals treating oncology patients, community oncology practices, and infusion centers throughout theU.S. ; - Secured access to LYMPHIR in 19 international markets through regional distribution partners via Named Patient Programs (NPPs), marking the first step in the Company's global access strategy; NPPs allow access to LYMPHIR where permitted by local law without constituting commercial approval outside the
U.S. ; - Announced a collaboration with Verix to deploy its Tovana AI-powered platform to enhance commercial targeting, real-time field execution, and provider engagement in support of LYMPHIR's
U.S. commercialization and adoption; and, - Announced promising preliminary results of an investigator-initiated Phase I clinical trial of pembrolizumab and LYMPHIR™ in cancer patients with recurrent solid tumors.
Fiscal Full Year 2025 Financial Highlights
- Cash and cash equivalents of
$3.9 million - Closed
$36 million - Completed an
$18 million - Completed a
$9 million - Completed a
$9 million - Received
$1 million - R&D expenses were
$6.4 million $4.9 million - G&A expenses were
$8.8 million $8.1 million - Stock-based compensation expense was
$8.3 million $7.5 million - Net loss was
$24.8 million $0.34 $21.1 million $0.31
About Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to maintain Nasdaq's continued listing standards; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com
-- Financial Tables Follow –
CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2025 AND 2024
| ||||||||
2025 | 2024 | |||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 3,924,908 | $ | 112 | ||||
Inventory | 22,286,693 | 8,268,766 | ||||||
Prepaid expenses | 1,331,280 | 2,700,000 | ||||||
Total Current Assets | 27,542,881 | 10,968,878 | ||||||
Other Assets: | ||||||||
In-process research and development | 73,400,000 | 73,400,000 | ||||||
Total Other Assets | 73,400,000 | 73,400,000 | ||||||
Total Assets | $ | 100,942,881 | $ | 84,368,878 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current Liabilities: | ||||||||
Accounts payable | $ | 13,234,684 | $ | 3,711,622 | ||||
License payable | 22,650,000 | 28,400,000 | ||||||
Accrued expenses | 4,093,124 | — | ||||||
Due to related party | 9,513,771 | 588,806 | ||||||
Total Current Liabilities | 49,491,579 | 32,700,429 | ||||||
Deferred tax liability | 2,784,960 | 1,728,000 | ||||||
Note payable to related party | 3,800,111 | 3,800,111 | ||||||
Total Liabilities | 56,076,650 | 38,228,540 | ||||||
Stockholders' Equity: | ||||||||
Preferred stock - | — | — | ||||||
Common stock - | 8,351 | 7,155 | ||||||
Additional paid-in capital | 108,897,836 | 85,411,771 | ||||||
Accumulated deficit | (64,039,956) | (39,278,587) | ||||||
Total Stockholders' Equity | 44,866,231 | 46,140,339 | ||||||
Total Liabilities and Stockholders' Equity | $ | 100,942,881 | $ | 84,368,878 | ||||
CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2025 AND 2024
| ||||||||
2025 | 2024 | |||||||
Revenues | $ | — | $ | — | ||||
Operating Expenses: | ||||||||
Research and development | 6,418,334 | 4,925,001 | ||||||
General and administrative | 8,783,997 | 8,148,929 | ||||||
Stock-based compensation – general and administrative | 8,320,419 | 7,498,817 | ||||||
Total Operating Expenses | 23,522,750 | 20,572,747 | ||||||
Operating loss | (23,522,750) | (20,572,747) | ||||||
Other Income (Expense) | ||||||||
Interest income | 36,373 | — | ||||||
Interest expense | (218,032) | — | ||||||
Total Other Income (Expense), Net | (181,659) | — | ||||||
Loss before Income Taxes | (23,704,409) | (20,572,747) | ||||||
Income tax expense | 1,056,960 | 576,000 | ||||||
Net Loss | $ | (24,761,369) | $ | (21,148,747) | ||||
Net Loss Per Share – Basic and Diluted | $ | (0.34) | $ | (0.31) | ||||
Weighted Average Common Shares Outstanding – Basic and Diluted | 73,267,969 | 68,053,607 | ||||||
CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2025 AND 2024
| ||||||||
2025 | 2024 | |||||||
Cash Flows From Operating Activities: | ||||||||
Net loss | $ | (24,761,369) | $ | (21,148,747) | ||||
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||||||||
Stock-based compensation expense | 8,320,419 | 7,498,817 | ||||||
Deferred income tax expense | 1,056,960 | 576,000 | ||||||
Changes in operating assets and liabilities: | ||||||||
Inventory | (12,649,207) | (2,133,871) | ||||||
Prepaid expenses | - | (1,100,000) | ||||||
Accounts payable | 9,523,062 | 2,422,577 | ||||||
Accrued expenses | 4,093,124 | (259,071) | ||||||
Due to related party | 8,924,965 | 14,270,648 | ||||||
Net Cash (Used in) Provided By Operating Activities | (5,492,046) | 126,353 | ||||||
Cash Flows From Investing Activities: | ||||||||
License payments | (5,750,000) | (5,000,000) | ||||||
Net Cash Used In Investing Activities | (5,750,000) | (5,000,000) | ||||||
Cash Flows From Financing Activities: | ||||||||
Net proceeds from issuance of common stock | 15,166,842 | - | ||||||
Cash contributed by parent | - | 3,827,944 | ||||||
Merger, net | - | (2,754,296) | ||||||
Proceeds from issuance of note payable to related party | - | 3,800,111 | ||||||
Net Cash Provided By Financing Activities | 15,166,842 | 4,873,759 | ||||||
Net Change in Cash and Cash Equivalents | 3,924,796 | 112 | ||||||
Cash and Cash Equivalents – Beginning of Year | 112 | - | ||||||
Cash and Cash Equivalents – End of Year | $ | 3,924,908 | $ | 112 | ||||
Supplemental Disclosures of Cash Flow Information and Non-cash Activities: | ||||||||
IPR&D Milestones included in License Payable | $ | - | $ | 28,400,000 | ||||
Capital Contribution of due to related party by parent | $ | - | $ | 33,180,961 | ||||
Net Prepaid Manufacturing transferred to Inventory | $ | 1,368,720 | $ | 6,134,895 | ||||
Interest Paid | $ | 187,389 | $ | - | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-year-2025-financial-results-and-provides-business-update-302648892.html
SOURCE Citius Oncology, Inc.
FAQ
When did Citius Oncology (CTOR) launch LYMPHIR in the U.S.?
How much financing did Citius Oncology (CTOR) secure to support LYMPHIR commercialization?
What was Citius Oncology's (CTOR) cash balance and net loss for fiscal 2025?
Which commercial steps has Citius Oncology (CTOR) taken to distribute LYMPHIR in the U.S.?
Has Citius Oncology (CTOR) secured international access for LYMPHIR?
What clinical progress did Citius Oncology (CTOR) report related to LYMPHIR?
